Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell CarcinomaJAMA Oncol 2021 Dec 23;[EPub Ahead of Print], RJ Motzer, T Powles, MB Atkins, B Escudier, DF McDermott, BY Alekseev, JL Lee, C Suarez, D Stroyakovskiy, U De Giorgi, F Donskov, B Mellado, R Banchereau, H Hamidi, O Khan, V Craine, M Huseni, N Flinn, S Dubey, BI Rini
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.